Description:

Testosterone for Peripheral Vascular Disease; ODM derived from: https://clinicaltrials.gov/show/NCT00504712

Link:

https://clinicaltrials.gov/show/NCT00504712

Keywords:
Versions (2) ▾
  1. 4/11/17
  2. 9/17/21
Uploaded on:

September 17, 2021

DOI:
No DOI assigned. To request one please log in.
License:
Creative Commons BY 4.0
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Hypogonadism NCT00504712

Eligibility Hypogonadism NCT00504712

  1. StudyEvent: Eligibility
    1. Eligibility Hypogonadism NCT00504712
Inclusion Criteria
1. type 2 diabetes mellitus.
2. serum testosterone 12 nmol/l or less on two consecutive samples taken on different days and symptoms compatible with hypogonadism.
3. peripheral vascular disease as defined by
previous diagnosis by a specialist vascular surgeon or
abpi less than 0.92 and ischaemic leg pain (claudication or rest pain) or distal complications (non-healing arterial foot ulcer or gangrene).
4. agreement to maintain antihypertensive and antilipid treatments at prior doses during 3 month duration of study.
5. ability to give written informed consent after verbal and written explanation in the english language.
6. ability to comply with all study requirements.
Exclusion Criteria
1. current or previous breast cancer.
2. current or previous prostate cancer.
3. raised prostate specific antigen (psa) or abnormal per rectal examination unless prostate cancer excluded after specialist urology opinion.
4. severe symptoms of benign prostatic hypertrophy (‘prostatism’)
5. treatment with testosterone in the 3 months prior to the trial.
6. investigational drug treatment in the 3 months prior to the trial.

Similar models